Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer

被引：0
|
作者：
Nishimura, S. [1 ]
Akiyoshi, S. [1 ]
Koga, C. [1 ]
Oikawa, M. [1 ]
Nskamura, Y. [1 ]
Ishida, M. [1 ]
Ohno, S. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Breast Oncol, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70209-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P168
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [31] Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2-metastatic breast cancer (MBC) using machine learning.
    Manuel Jerez, Jose
    Ribelles, Nuria
    Rodriguez-Brazzarola, Pablo
    Diaz Redondo, Tamara
    Jimenez Rodriguez, Begona
    Sanchez-Munoz, Alfonso
    Marquez, Antonia
    Carabantes, Francisco
    Pajares, Bella
    Villar, Ester
    Bermejo-Perez, Maria-Jose
    Saez Lara, Enrique
    Emilia Dominguez-Recio, Maria
    Godoy, Ana
    Mesa, Hector
    Galvez Carvajal, Laura
    Franco, Leo
    Ruiz, Sofia
    Lopez, Irene
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
    Maryam Soleimani Dodaran
    Simone Borgoni
    Emre Sofyalı
    Pernette J. Verschure
    Stefan Wiemann
    Perry D. Moerland
    Antoine H. C. van Kampen
    BMC Cancer, 20
  • [34] Aromatase inhibitor failure: predictors and time to first failure among women with metastatic ER+/HER2-breast cancer in the US
    Thomson, E.
    Namjoshi, M.
    Landsman-Blumberg, P.
    Chu, B. C.
    CANCER RESEARCH, 2012, 72
  • [35] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [36] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer
    Dodaran, Maryam Soleimani
    Borgoni, Simone
    Sofyali, Emre
    Verschure, Pernette J.
    Wiemann, Stefan
    Moerland, Perry D.
    van Kampen, Antoine H. C.
    BMC CANCER, 2020, 20 (01)
  • [37] ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2-metastatic breast cancer: A phase 3 trial
    Bidard, Francois Clement
    Bellesoeur, Audrey
    Hajjaji, Nawale
    Rowinski, Elise
    De Nonneville, Alexandre
    Alexandre, Marie
    Lalire, Paul
    Deleuze, Antoine
    Alix-Panabieres, Catherine
    Turbiez, Isabelle
    Berger, Frederique
    Seban, Romain-David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2-Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2-Breast Cancer
    Rosswag, Sven
    Cotarelo, Cristina L.
    Pantel, Klaus
    Riethdorf, Sabine
    Sleeman, Jonathan P.
    Schmidt, Marcus
    Thaler, Sonja
    CANCERS, 2021, 13 (08)
  • [40] Sequential second line endocrine therapy is still an effective strategy for postmenopausal ER+ and HER2-advanced breast cancer with low sensitivity to initial endocrine therapy
    Araki, K.
    Fujisawa, T.
    Sakamaki, K.
    Kikawa, Y.
    Iwamoto, T.
    Sangai, T.
    Shien, T.
    Takao, S.
    Nishimura, R.
    Takahashi, M.
    Aihara, T.
    Mukai, H.
    Taira, N.
    CANCER RESEARCH, 2019, 79 (04)
12345